No connection

Search Results

GDRX vs LXRX

GDRX
GoodRx Holdings, Inc.
BEARISH
Price
$2.16
Market Cap
$740.0M
Sector
Healthcare
AI Confidence
85%
LXRX
Lexicon Pharmaceuticals, Inc.
NEUTRAL
Price
$1.71
Market Cap
$724.5M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
GDRX
24.0
LXRX
--
Forward P/E
GDRX
5.88
LXRX
-8.22
P/B Ratio
GDRX
1.2
LXRX
5.78
P/S Ratio
GDRX
0.93
LXRX
14.55
EV/EBITDA
GDRX
8.35
LXRX
-14.3

Profitability

Gross Margin
GDRX
92.77%
LXRX
86.82%
Operating Margin
GDRX
18.98%
LXRX
-269.07%
Profit Margin
GDRX
3.82%
LXRX
-101.08%
ROE
GDRX
4.54%
LXRX
-39.72%
ROA
GDRX
4.75%
LXRX
-12.65%

Growth

Revenue Growth
GDRX
-1.9%
LXRX
-79.3%
Earnings Growth
GDRX
-9.7%
LXRX
--

Financial Health

Debt/Equity
GDRX
0.88
LXRX
0.58
Current Ratio
GDRX
2.61
LXRX
4.88
Quick Ratio
GDRX
2.1
LXRX
4.73

Dividends

Dividend Yield
GDRX
--
LXRX
--
Payout Ratio
GDRX
0.0%
LXRX
0.0%

AI Verdict

GDRX BEARISH

GDRX exhibits a fragile financial profile with a Piotroski F-Score of 4/9, indicating only marginal stability. The stock is currently trading at $2.16, which is a premium to its Graham Number ($1.91) and significantly above its growth-based intrinsic value ($0.63). Fundamental decay is evident through negative YoY revenue (-1.90%) and earnings growth (-9.70%), compounded by a streak of four consecutive earnings misses. With a 5-year price collapse of 94.7% and bearish insider sentiment, the data suggests a company in a structural decline.

Strengths
Exceptionally high gross margins (92.77%)
Strong short-term liquidity with a current ratio of 2.61
Low Price-to-Sales ratio (0.93) suggesting low valuation relative to revenue
Risks
Negative revenue and earnings growth trends
Consistent failure to meet analyst earnings estimates (0/4 last 4 quarters)
Severe long-term price erosion (-94.7% over 5 years)
LXRX NEUTRAL

LXRX exhibits a high-risk, speculative profile with a Piotroski F-Score of 4/9, indicating stable but mediocre financial health. While the company maintains a strong liquidity cushion (Current Ratio 4.88) and has consistently beaten earnings estimates in recent quarters, the fundamental revenue collapse (-79.3% YoY) is a critical red flag. Despite a massive 1-year price surge of 222.6%, the current technical trend is heavily bearish (10/100), suggesting the rally may have peaked. The valuation remains disconnected from current fundamentals, relying entirely on future pipeline success or analyst optimism.

Strengths
Strong liquidity position with a Current Ratio of 4.88
High Gross Margin of 86.82% indicating strong product pricing power
Consistent recent earnings beats (3 of last 4 quarters)
Risks
Severe revenue contraction (-79.3% YoY and Q/Q)
Deeply negative operating margins (-269.07%)
Strongly bearish technical trend (10/100)

Compare Another Pair

GDRX vs LXRX: Head-to-Head Comparison

This page compares GoodRx Holdings, Inc. (GDRX) and Lexicon Pharmaceuticals, Inc. (LXRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile